The dynamics of medical care in skin cancers by Dummer, Reinhard
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
The dynamics of medical care in skin cancers
Dummer, Reinhard
DOI: https://doi.org/10.1097/CCO.0000000000000435
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-150229
Journal Article
Published Version
Originally published at:
Dummer, Reinhard (2018). The dynamics of medical care in skin cancers. Current Opinion in Oncology,
30(2):105-106.
DOI: https://doi.org/10.1097/CCO.0000000000000435
 CURRENTOPINION The dynamics of medical care in skin cancers
Reinhard Dummer
Ten years ago, surgery was the only reliable treat-
ment option in most skin cancers. Medical therapy
including chemotherapy was standard of care with-
out any benefit concerning overall survival.
Many patients with advanced melanoma
received monochemotherapy with dacarbazine for
metastatic disease. Others were treated with high-
dose interleukin 2. This treatment causes substantial
side-effects and many medical complications.
In the adjuvant situation, high-dose interferon a
was used. Interferon a has an impact on the out-
come, however, again this therapy was quiet toxic.
Many patients suffered for months from flu-like
symptoms and some also from depression. On the
basis of a very limited repertoire of treatment
options, many patients searched for alternative
medicine strategies or other obscured treatment
options.
Today, advanced melanoma is a paradigm for
modern tumor therapy including targeted and
immunotherapy.
The Progressive Disease (PD) ligand 1 and 2/PD1
interaction is very important for the prevention of
autoimmunity in cutaneous cardiac, kidney and
other tissues. Nevertheless, the use of anti-PD1 anti-
bodies is very safe and tolerable. There are currently
some adverse events, but the risk ratio benefit is very
much in favor of this therapy.
Anti-PD1 therapies are really the backbone for
immunotherapy in melanoma.
They are really successful treatment options
with a reasonable response rate and a low risk for
adverse events. However, there are a number of
patients who do not respond to the monotherapy;
therefore, there is an urgent need for combined
immunotherapy.
Combined immunotherapy has resulted in a
58% 3-year survival landmark for the combination
therapy of ipilimumab and nivolumab [1].
We have seen that combinations are more
powerful concerning progression-free survival and
response rates, but now for the first time we have
the proof of concept that the addition of a second
immune modulator improves overall outcome. Cer-
tainly, the drawback is that we have more toxicity;
however, we can work on this. So, first, we can
improve the management of patients on combined
immunotherapies, or we can use other immune
modulators such as anti-tumor necrosis factor
strategies earlier.
Moreover, we can search for additional combi-
nation agents that are specifically selected for the
individual patient, such as concept precision immu-
notherapy. With this, there is a good chance that
the overall outcome of immunotherapy will be
improved. A new molecule in development is epa-
cadostat, an IDO1 inhibitor that has demonstrated
promising progression-free survival, as well as
a good response rate and favorable safety profile
compared with current monotherapies.
Targeted therapies achieve response rates of
more than 80% in brain rapidly accelerated fibro-
sarcoma mutant-advanced melanomas. It was a log-
ical consequence to apply these powerful treatment
options to the early, adjuvant therapy after com-
plete resection. As expected, the results available
and together with recent findings on the value of
surgical procedures necessitate a complete revision
of current treatment guidelines. This process is com-
plicated by the introduction of new American Joint
Committee on Cancer staging classification systems
[2]. There is intriguing evidence that targeted thera-
pies help to create a beneficial microenvironment in
tumor tissues [3]. The clinical data of dabrafenib/
tramatenib in the adjuvant setting [4] conveniently
show a lasting benefit of the patient even years after
the discontinuation of the kinase inhibitors. This
suggests long-term effects probably by modification
of immune functions and deserves careful scientific
evaluations.
As outlined above, immunoncology is and
remains a major driver of progress for melanoma
and other cutaneous malignancies such as angiosar-
coma. This rare figuring of cutaneous malignancy is
another topic of the review articles in this section.
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